Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Prostate specific membrane antigen (PSMA) has become an attractive diagnostic and therapeutic target for small molecule ligands. Radionuclide-chelating ligands can be labeled with either68Ga for positron-emission-tomography (PET) or177Lu for radionuclide therapy. Areas covered: In this literature review we evaluate the diagnostic value of68Ga PSMA PET/CT and the therapeutic potential of177Lu PSMA radioligand therapy (RLT) in patients with prostate cancer.68Ga PSMA PET/CT is more accurate than CT for nodal staging and superior to conventional imaging in patients with biochemical recurrence, translating into major changes in clinical management. The preliminary data for177Lu PSMA indicates >50% reduction of PSA levels in up to 59% of patients. Severe adverse events occurred <10% of patients after RLT. Expert commentary: PSMA ligands for diagnostic and therapeutic purpose will significantly impact the management of patients with prostate cancer.
a Department of Molecular and Medical Pharmacology , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.
Martin
M
Barrio
a Department of Molecular and Medical Pharmacology , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.|b Department of Nuclear Medicine , Ludwig-Maximilians-University of Munich , Munich , Germany.
Wolfgang P
WP
Fendler
a Department of Molecular and Medical Pharmacology , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.
Johannes
J
Czernin
a Department of Molecular and Medical Pharmacology , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.|c Department of Nuclear Medicine , University Hospital Essen , Essen , Germany.
Ken
K
Herrmann
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface / Q000378:metabolism*; D014408:Biomarkers, Tumor; D019468:Disease Management; D043425:Glutamate Carboxypeptidase II / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D008279:Magnetic Resonance Imaging; D008297:Male; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D000072078:Positron Emission Tomography Computed Tomography; D049268:Positron-Emission Tomography / Q000379:methods; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000628:therapy; D019275:Radiopharmaceuticals; D000068936:Theranostic Nanomedicine / Q000379:methods
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D014408:Biomarkers, Tumor; D008024:Ligands; D019275:Radiopharmaceuticals; C101315:Capromab Pendetide; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D017430:Prostate-Specific Antigen
Gallium; Lutetium; PET; PSMA; prostate cancer; theranostic; therapy